Comprehensive behavioral and biochemical outcomes of novel murine models of GM1-gangliosidosis and Morquio syndrome type B

Michael J. Przybilla, Li Ou, Alexandru Flaviu Tăbăran, Xuntian Jiang, Rohini Sidhu, Pamela J. Kell, Daniel S. Ory, M. Gerard O'Sullivan, Chester B. Whitley

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Deficiencies in the lysosomal hydrolase β-galactosidase (β-gal) lead to two distinct diseases: the skeletal disease Morquio syndrome type B, and the neurodegenerative disease GM1-gangliosidosis. Utilizing CRISPR-Cas9 genome editing, the mouse β-gal encoding gene, Glb1, was targeted to generate both models of β-gal deficiency in a single experiment. For Morquio syndrome type B, the common human missense mutation W273L (position 274 in mice) was introduced into the Glb1 gene (Glb1 W274L ), while for GM1-gangliosidosis, a 20 bp mutation was generated to remove the catalytic nucleophile of β-gal (β-gal −/− ). Glb1 W274L mice showed a significant reduction in β-gal enzyme activity (8.4–13.3% of wildtype), but displayed no marked phenotype after one year. In contrast, β-gal −/− mice were devoid of β-gal enzyme activity (≤1% of wildtype), resulting in ganglioside accumulation and severe cellular vacuolation throughout the central nervous system (CNS). β-gal −/− mice also displayed severe neuromotor and neurocognitive dysfunction, and as the disease progressed, the mice became emaciated and succumbed to the disease by 10 months of age. Overall, in addition to generating a novel murine model that phenotypically resembles GM1-gangliosidosis, the first model of β-galactosidase deficiency with residual enzyme activity has been developed.

Original languageEnglish (US)
Pages (from-to)139-150
Number of pages12
JournalMolecular Genetics and Metabolism
Volume126
Issue number2
DOIs
StatePublished - Feb 2019

Bibliographical note

Funding Information:
Quantification of gangliosides was supported through funding from the National Tay-Sachs & Allied Diseases Association, Inc. (NTSAD). We thank Dr. Shunji Tomatsu at the University of Delaware for providing his expertise in quantifying plasma keratan sulfate. Generation of ?-galactosidase deficient mice was performed at the Animal Models Core Facility at the University of North Carolina at Chapel Hill under the direction of Dr. Dale Cowley.

Funding Information:
Quantification of gangliosides was supported through funding from the National Tay-Sachs & Allied Diseases Association , Inc. (NTSAD). We thank Dr. Shunji Tomatsu at the University of Delaware for providing his expertise in quantifying plasma keratan sulfate. Generation of β-galactosidase deficient mice was performed at the Animal Models Core Facility at the University of North Carolina at Chapel Hill under the direction of Dr. Dale Cowley.

Publisher Copyright:
© 2018 The Authors

Keywords

  • Gangliosidosis
  • Lysosomal disease
  • Mouse Model
  • Mucopolysaccharidosis

Fingerprint Dive into the research topics of 'Comprehensive behavioral and biochemical outcomes of novel murine models of GM1-gangliosidosis and Morquio syndrome type B'. Together they form a unique fingerprint.

Cite this